Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate

NCT01370629 is registered in ClinicalTrials.gov with Correvio International Sarl as lead sponsor.

NCT NCT01370629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01370629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate
Lead sponsor
Correvio International Sarl
Phase
Observational
Overall status
Completed
Start date
August 31, 2011
Completion date
May 8, 2018
Enrollment
2,015 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation